상세 보기
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
- Sim, S.H.;
- Kim, J.E.;
- Kim, M.H.;
- Park, Y.H.;
- Kim, J.H.;
- ... Kim, H.-J.;
- 외 16명
Citations
WEB OF SCIENCE
2Citations
SCOPUS
3초록
We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.
키워드
HER2 positive; Metastatic breast cancer; Trastuzumab biosimilar; Clinical trialct; DNA; DOUBLE-BLIND; PROGRESSION; RETREATMENT; GUIDELINE; MUTATIONS; EMTANSINE; LAPATINIB; HER2
- 제목
- Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
- 저자
- Sim, S.H.; Kim, J.E.; Kim, M.H.; Park, Y.H.; Kim, J.H.; Suh, K.J.; Koh, S.-J.; Park, K.H.; Kang, M.J.; Ahn, M.S.; Lee, K.E.; Kim, H.-J.; Ahn, H.K.; Kim, H.J.; Park, K.U.; Byun, J.H.; Park, J.H.; Lee, G.-W.; Lee, K.S.; Sohn, J.; Jung, K.H.; Park, I.H.
- 발행일
- 2022-10
- 유형
- Article
- 저널명
- Breast
- 권
- 65
- 페이지
- 172 ~ 178
- 언어
- ENG
- 출판사
- Churchill Livingstone
- 발행국가
- 영국
- 분량
- 7 페이지
- ISSN
- E 1532-3080
P 0960-9776